Skip to content


  • Research
  • Open Access

Anti-Mullerian hormone levels decline under hormonal suppression: a prospective analysis in fertile women after delivery

  • 1, 2Email author,
  • 1, 3,
  • 4,
  • 5,
  • 2, 6 and
  • 2, 7
Reproductive Biology and Endocrinology20119:98

  • Received: 28 April 2011
  • Accepted: 21 July 2011
  • Published:



AMH's reported stability during periods of hormonal change makes it a practical tool in assessing ovarian reserve. However, AMH declines with age and age-specific cut-offs remain to be established in women with proven fertility. This study aims to determine age-specific ranges of AMH in women with proven fertility.


Two hundred-ten fertile women, aged 18-40 years, were prospectively recruited for AMH measurements within 14 days after delivery and age stratified into 3 groups (18-30, 31-36 and 37-40 years). Eligibility required spontaneous conception within a maximal period of six months. Autoimmune diseases, chemotherapy, radiation, ovarian surgery and polycystic ovary syndrome precluded inclusion.


95% confidence intervals of AMH declined with advancing female age from 0.9-1.1 to 0.6-0.9 and 0.2-0.4 ng/mL (P < 0.001). AMH levels were not statistically associated with day of blood draw after delivery or pregnancy characteristics. Neither were they predictive of resumption of menses. They, however, at all ages were lower than reported in the literature for infertile patients.


Like infertile populations, fertile women demonstrate declining AMH with advancing age. Uniformly lower levels than in infertile women suggest that AMH levels do not appear as stable under all hormonal influences as previously reported.


  • Polycystic Ovary Syndrome
  • Ovarian Reserve
  • Antral Follicle
  • Infertile Patient
  • Antral Follicle Count


Accurate assessments of ovarian reserve are crucial and allow for appropriate counselling during women's reproductive life spans. Anti-Müllerian hormone (AMH) is increasingly used as diagnostic marker in assessing ovarian reserve (OR). Indeed, we and others reported improved accuracy in predicting oocyte yields and pregnancy potential, compared to baseline follicle stimulating hormone (b-FSH) [1, 2].

Anti-Müllerian hormone is produced in granulosa cells of small follicles from primary stage on [3, 4]. By inhibiting follicular recruitment [3], AMH exerts regulative functions on folliculogenesis, and serum concentrations are relatively closely reflective of numbers of antral follicles [5, 6]. Antral follicle counts are, however, widely believed to be directly proportional to a woman's total follicle pool and, therefore, reflective of her OR [3, 5, 7]. AMH's reported stability during periods of hormonal change, such as menstrual cycles and in association with pregnancy, supports the assumption that AMH may, indeed, be reflective of a woman's total follicle pool [810]. This AMH characteristic also makes it a more practical clinical tool in comparison to other modalities [11].

AMH, however, gradually declines as women age [12, 13]. Among infertile patients, substantially higher percentages of women at both extremes of AMH values (i.e., diminished ovarian reserve and polycystic ovary syndrome) are observed. Currently available age-specific normograms were usually established in infertile patient populations [14]. In an attempt to establish age-specific values in a fertile cohort, Shebl et al. retrospectively investigated AMH levels in women undergoing IVF due to male factor or idiopathic infertility. Their results, however, clearly demonstrate compromised AMH levels (i.e. ≤1 ng/ml) in 5% of women throughout all ages. They, therefore, conclude that even young 'presumbly healthy' women undergoing IVF are at risk of diminishing ovarian reserve. Moreover, no data on pregnancy potential in those women are given [14]. Age-specific AMH cut-offs, established in a population with proven fertility, would, therefore, be useful to accurately diagnose normal age-specific ovarian reserve or prematurely declining ovarian reserve, respectively. To determine such age-specific cut-offs, AMH measurements were initiated in a cohort of women shortly after delivery after spontaneous conception within six months of unprotected intercourse.


Between April 2008 and September 2009, prospective recruitment of 210 women with proven fertility in three age strata (n = 70 in each group; Group 1, 18-30 years; Group 2, 31-36 years; Group 3, 37-40 years) was performed. Recruitment occurred within four and consecutive blood draw for AMH measurement within 14 days after delivery at the Department of Obstetrics & Gynecology, Medical University Vienna, Austria. Follow up telephone interviews were completed six to 24 months after delivery.

Women were eligible for enrollment if they had conceived spontaneously within six months and were excluded with a history of infertility, autoimmune disease, chemo/radiation therapy, ovarian surgery and polycystic ovary syndrome. All AMH measurements were performed at the Department of Medical Laboratory Diagnostics, Medical University Vienna, using the DSL Active MIS/AMH assay (Beckman Coulter Inc., USA).

After the completion of recruitment, one-hundred-and-four women were available for follow up telephone interview six to 24 months after delivery and asked about current contraceptive methods utilized, duration of breast feeding and resumption of menses.

In order to establish required sample sizes, differences in age-related AMH levels were calculated according to Shebl et al. [14]. To detect a comparable decline of AMH between the Groups with 80% power and 0.1% level of significance, a sample size of 62 per group was needed. We, therefore, decided to recruit 70 women per age strata.

Baseline characteristics of patients and AMH levels were compared between the Groups 1 to 3, using analyses of variance or chi square, as appropriate. Variables that were not normally distributed were first log transformed, and are reported as geometric means and 95% confidence intervals (CI). Normally distributed variables were reported as means ± standard deviation (SD). We used linear regression to assess effects of baseline characteristics, postpartum AMH on pregnancy and postpartum factors. A p-value < 0.05 was considered statistically significant. Statistical analyses were performed using SPSS version 17.0.

Institutional Review Board (IRB) approval was obtained from the Ethics Committee at the Medical University Vienna. After recruitment, all patients signed appropriate informed consents.


Baseline characteristics in the three age strata are shown in Table 1. Mean age for all study patients was 32.4 ± 5.7 years. Mean postpartum AMH levels were 0.6 ng/ml (95% CI, 0.5-0.7). AMH determinations were made at an average of 3.4 ± 2.1 days after delivery. Patients delivered at a mean gestational age of 38.0 ± 3.2 weeks.
Table 1

Baseline characteristics & outcome data of 210 fertile women within 14 days after delivery according to age

(n = 70 per group)

Group 1

Group 2

Group 3



(18-30 years)

(31-36 years)

(37-40 years)


Female age (years)

25.7 ± 3.5


33.4 ± 1.6


38.2 ± 1.1



Postpartum AMH (ng/ml)








Delivery to AMH draw (days)

3.4 ± 2.3


3.6 ± 2.3


3.1 ± 1.6



Delivery to resumption of menses (months)








Gestational age at delivery

37.9 ± 3.2


38.0 ± 2.9


38.1 ± 3.6



Normally distributed variables are presented as mean ± SD and 95%CI, not normally distributed variables are presented as log transformed means with 95 CI.

AMH levels were negatively associated with age (p < 0.0001). Average AMH levels by age group were: 0.9 ng/ml (95% CI, 0.7-1.1) in Group 1, 0.7 ng/ml (95% CI, 0.6-0.9) in Group 2, and 0.2 ng/ml in Group 3 (95% CI, 0.2-0.4). There was no difference between age groups in gestational age at delivery, mode of delivery, fetal gender, birth weight and intervals between deliveries and AMH draw.

Due to the considerably long time period of up to 24 months between recruitment and follow up, only 104 women were available for a telephone interview. Among those, menses resumed after mean duration of 3.4 months (95% CI, 2.6-4.4) in Group 1, after 4.5 months (95% CI, 3.7-5.3) in Group 2, and after 5.3 months (95% CI, 3.9-6.8) in Group 3. The interval to onset of menses increased significantly with increasing age (p < 0.03) and was proportionally delayed with the duration of breast feeding (p < 0.001). Women who completed follow up were evenly distributed between the age strata.

Using linear regression we found no significant association between AMH levels and onset of menses. After constructing multiple linear regression models, adjusted for age, duration of breast feeding and hormonal contraception usage, there was still no significant effect of AMH levels on onset of menses.


Our results demonstrate gradually declining AMH levels with age in fertile women, similar to declines reported in infertile populations [15]. They, however, also show substantially lower AMH levels postpartum than reported in infertile patients [10, 14]. This, most likely, reflects a suppressive effect of pregnancy/puerperium on growing follicle cohorts and, thus, AMH. Though patient age and duration of breast feedings significantly influenced intervals to resumption of menses, AMH levels did not.

This study investigated only women with proven fertility. It, therefore, appears unlikely that the observed, apparently suppressed, AMH levels postpartum reflect their actual total follicle pool. The substantially reduced AMH concentrations postpartum may, therefore, mirror lower folliculogenesis after delivery. These assumptions are supported by the delay of menopause in multiparous women [16, 17].

Recent findings of Nelson et al. are in accordance with the assumption of a suppressive effect of hormonal changes on AMH levels: They reported declining AMH levels during second and third trimesters of pregnancy [18], contradicting prior observations that claimed AMH to be stable during pregnancy and puerperium [19, 20]. Also contrary to prior reports [21], AMH may also be suppressed with oral contraceptives [22]. Van den Berg et al. recently reported that AMH on day seven of contraception free intervals does not correspond to AMH values in subsequent natural cycles. They reported not only increasing AMH levels immediately after cessation of contraception, but even higher levels after two months from cessation [22].

Data from women with polycystic ovary syndrome (PCOS) after ovarian drilling further support the point: Shebl et al. report decreased AMH levels shortly after ovarian drilling, when compared to pre-surgery levels. AMH, however, returned to approximately original levels within six months from surgery [23].

All of these data raise questions as to what extent, and under which conditions, AMH is reflective of the total follicle pool. It, indeed, appears possible that AMH primarily reflects growing follicles (i.e. an actively maturing follicle cohort), but not - or not under all circumstances - the complete follicle pool. Further studies are, therefore, warranted to evaluate factors that might possibly interfere with AMH secretion or rather under which conditions AMH concentrations can be utilized to assess ovarian reserve.

This study, as one would expect, also demonstrates a significant decline of AMH levels with age in fertile women. Fertile women, further, show a significant correlation between age and resumption of menses - the older a woman is at the time of delivery the longer it takes to resume menses. Latter correlation could reflect declines in ovarian reserve with advancing female age, and one, therefore, would expect a comparable association between postpartum AMH levels and resumption of menses (corrected for breast feeding and hormonal contraceptive usage), if AMH, indeed, was reflective of total ovarian follicle pools. Our data, however, clearly failed to demonstrate such an association. Though data on resumption of menses were not available for the whole cohort of 210 women, this lack of association was seen in all three age groups.


Like infertile populations, fertile women demonstrate declining AMH with advancing age. Uniformly lower levels than in infertile women suggest that AMH levels do not appear as stable under all hormonal influences as previously reported.


Authors’ Affiliations

Department of Obstetrics & Gynecology, Medical University Vienna, Austria
The Center for Human Reproduction (CHR), New York and The Foundation for Reproductive Medicine, Chicago, Illinois, USA
Department of Obstetrics & Gynecology, General Hospital Mistelbach, Austria
General Hospital Moedling, Austria
Department of Medical Laboratory Diagnostics, Medical University Vienna, Austria
Department of Epidemiology and Social Medicine and Department of Gynecology and Women's Health, Albert Einstein College of Medicine, Bronx, New York, USA
Department of Obstetrics, Gynecology and Reproductive Sciences, Yale University School of Medicine, New Haven, Connecticut, USA


  1. Singer T, Barad DH, Weghofer A, Gleicher N: Correlation of antimullerian hormone and baseline follicle-stimulating hormone levels. Fertil Steril. 2009, 91 (6): 2616-2619. 10.1016/j.fertnstert.2008.03.034.View ArticlePubMedGoogle Scholar
  2. McIlveen M, Skull JD, Ledger WL: Evaluation of the utility of multiple endocrine and ultrasound measures of ovarian reserve in the prediction of cycle cancellation in a high-risk IVF population. Hum Reprod. 2007, 22 (3): 778-785.View ArticlePubMedGoogle Scholar
  3. Broer SL, Mol B, Dolleman M, Fauser BC, Broekmans FJ: The role of anti-Mullerian hormone assessment in assisted reproductive technology outcome. Curr Opin Obstet Gynecol. 2010, 22 (3): 193-201. 10.1097/GCO.0b013e3283384911.View ArticlePubMedGoogle Scholar
  4. Ebner T, Sommergruber M, Moser M, Shebl O, Schreier-Lechner E, Tews G: Basal level of anti-Mullerian hormone is associated with oocyte quality in stimulated cycles. Hum Reprod. 2006, 21 (8): 2022-2026. 10.1093/humrep/del127.View ArticlePubMedGoogle Scholar
  5. van Houten EL, Themmen AP, Visser JA: Anti-Mullerian hormone (AMH): regulator and marker of ovarian function. Ann Endocrinol (Paris). 2010, 71 (3): 191-197.View ArticleGoogle Scholar
  6. Andersen CY, Schmidt KT, Kristensen SG, Rosendahl M, Byskov AG, Ernst E: Concentrations of AMH and inhibin-B in relation to follicular diameter in normal human small antral follicles. Hum Reprod. 2010, 25 (5): 1282-1287. 10.1093/humrep/deq019.View ArticlePubMedGoogle Scholar
  7. Jayaprakasan K, Deb S, Batcha M, Hopkisson J, Johnson I, Campbell B, Raine-Fenning N: The cohort of antral follicles measuring 2-6 mm reflects the quantitative status of ovarian reserve as assessed by serum levels of anti-Mullerian hormone and response to controlled ovarian stimulation. Fertil Steril. 2010, 94 (5): 1775-1781. 10.1016/j.fertnstert.2009.10.022.View ArticlePubMedGoogle Scholar
  8. La Marca A, Sighinolfi G, Radi D, Argento C, Baraldi E, Artenisio AC, Stabile G, Volpe A: Anti-Mullerian hormone (AMH) as a predictive marker in assisted reproductive technology (ART). Hum Reprod Update. 2010, 16 (2): 113-130. 10.1093/humupd/dmp036.View ArticlePubMedGoogle Scholar
  9. La Marca A, Stabile G, Artenisio AC, Volpe A: Serum anti-Mullerian hormone throughout the human menstrual cycle. Hum Reprod. 2006, 21 (12): 3103-3107. 10.1093/humrep/del291.View ArticlePubMedGoogle Scholar
  10. Broer SL, Eijkemans MJ, Scheffer GJ, van Rooij IA, de Vet A, Themmen AP, Laven JS, de Jong FH, Te Velde ER, Fauser BC, et al: Anti-Mullerian Hormone Predicts Menopause: A Long-Term Follow-Up Study in Normoovulatory Women. J Clin Endocrinol Metab.Google Scholar
  11. Tremellen K, Kolo M: Serum anti-Mullerian hormone is a useful measure of quantitative ovarian reserve but does not predict the chances of live-birth pregnancy. Aust N Z J Obstet Gynaecol. 2010, 50 (6): 568-572. 10.1111/j.1479-828X.2010.01232.x.View ArticlePubMedGoogle Scholar
  12. Lee TH, Liu CH, Huang CC, Hsieh KC, Lin PM, Lee MS: Impact of female age and male infertility on ovarian reserve markers to predict outcome of assisted reproduction technology cycles. Reprod Biol Endocrinol. 2009, 7: 100-10.1186/1477-7827-7-100.PubMed CentralView ArticlePubMedGoogle Scholar
  13. Lambalk CB, van Disseldorp J, de Koning CH, Broekmans FJ: Testing ovarian reserve to predict age at menopause. Maturitas. 2009, 63 (4): 280-291. 10.1016/j.maturitas.2009.06.007.View ArticlePubMedGoogle Scholar
  14. Shebl O, Ebner T, Sir A, Schreier-Lechner E, Mayer RB, Tews G, Sommergruber M: Age-related distribution of basal serum AMH level in women of reproductive age and a presumably healthy cohort. Fertil Steril. 2011, 95 (2): 832-834. 10.1016/j.fertnstert.2010.09.012.View ArticlePubMedGoogle Scholar
  15. Nardo LG, Christodoulou D, Gould D, Roberts SA, Fitzgerald CT, Laing I: Anti-Mullerian hormone levels and antral follicle count in women enrolled in in vitro fertilization cycles: relationship to lifestyle factors, chronological age and reproductive history. Gynecol Endocrinol. 2007, 23 (8): 486-493. 10.1080/09513590701532815.View ArticlePubMedGoogle Scholar
  16. Loh FH, Khin LW, Saw SM, Lee JJ, Gu K: The age of menopause and the menopause transition in a multiracial population: a nation-wide Singapore study. Maturitas. 2005, 52 (3-4): 169-180. 10.1016/j.maturitas.2004.11.004.View ArticlePubMedGoogle Scholar
  17. Mishra G, Hardy R, Kuh D: Are the effects of risk factors for timing of menopause modified by age? Results from a British birth cohort study. Menopause. 2007, 14 (4): 717-724.PubMedGoogle Scholar
  18. Nelson SM, Stewart F, Fleming R, Freeman DJ: Longitudinal assessment of antimullerian hormone during pregnancy-relationship with maternal adiposity, insulin, and adiponectin. Fertil Steril. 2010, 93 (4): 1356-1358. 10.1016/j.fertnstert.2009.07.1676.View ArticlePubMedGoogle Scholar
  19. La Marca A, Giulini S, Orvieto R, De Leo V, Volpe A: Anti-Mullerian hormone concentrations in maternal serum during pregnancy. Hum Reprod. 2005, 20 (6): 1569-1572. 10.1093/humrep/deh819.View ArticlePubMedGoogle Scholar
  20. La Marca A, Giulini S, Tirelli A, Bertucci E, Marsella T, Xella S, Volpe A: Anti-Mullerian hormone measurement on any day of the menstrual cycle strongly predicts ovarian response in assisted reproductive technology. Hum Reprod. 2007, 22 (3): 766-771.View ArticlePubMedGoogle Scholar
  21. Somunkiran A, Yavuz T, Yucel O, Ozdemir I: Anti-Mullerian hormone levels during hormonal contraception in women with polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol. 2007, 134 (2): 196-201. 10.1016/j.ejogrb.2007.01.012.View ArticlePubMedGoogle Scholar
  22. van den Berg MH, van Dulmen-den Broeder E, Overbeek A, Twisk JW, Schats R, van Leeuwen FE, Kaspers GJ, Lambalk CB: Comparison of ovarian function markers in users of hormonal contraceptives during the hormone-free interval and subsequent natural early follicular phases. Hum Reprod. 2010, 25 (6): 1520-1527. 10.1093/humrep/deq071.View ArticlePubMedGoogle Scholar
  23. Shebl O, Sommergruber M, Ebner T, Sir A, Tews G: Serum AMH levels in women with PCOS. Annual Meeting of the Austrian Society of Obstetrics & Gynecology. 2009Google Scholar


© Weghofer et al; licensee BioMed Central Ltd. 2011

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.